<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04538313</url>
  </required_header>
  <id_info>
    <org_study_id>KT-2020-TIL001</org_study_id>
    <nct_id>NCT04538313</nct_id>
  </id_info>
  <brief_title>A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs</brief_title>
  <official_title>Early Clinical Trials on Evaluating the Tolerance, Safety and Efficacy of Autologous TILs in High-risk Recurrent Primary Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAR-T (Shanghai) Cell Biotechnology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CAR-T (Shanghai) Cell Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early clinical trials on evaluating the tolerance, safety and efficacy of autologous TILs in&#xD;
      high-risk recurrent primary hepatocellular carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the tolerability and safty of autologous TILs in high-risk recurrent primary hepatocellular carcinoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the tolerability and safty of autologous TILs in high-risk recurrent primary hepatocellular carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D score</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate the efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^10 TIL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10^9 TIL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension set</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The number of TIL is decided by dose escalation experiment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tumor infiltrating lymphocyte</intervention_name>
    <description>Tumor infiltrating lymphocytes were isolated from tumor tissues from tumor biopsy or operation. These TILs were cultured in human IL-2 medium for 4 to 5 weeks. 10e9 to 10e10 TILs were yielded. The phenotype, function and sterile were detected before these TILs infused patients.</description>
    <arm_group_label>Extension set</arm_group_label>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years, gender unlimited;&#xD;
&#xD;
          2. Patients diagnosis of primary hepatocellular carcinoma by histopathology and/or&#xD;
             cytology;&#xD;
&#xD;
          3. At the initial enrollment evaluation, patients were expected to accept radical&#xD;
             resection of liver cancer and meet at least one of the following high-risk recurrence&#xD;
             factors after surgery: ①There are 3 or more tumor lesions in the liver; ②The diameter&#xD;
             of a single tumor lesion is &gt;8cm; ③Existence macrovascular tumor thrombus; ④&gt;5 MVI or&#xD;
             MVI occurred in the distant paracancer tissues;&#xD;
&#xD;
          4. Before enrollment (after radical resection of liver cancer), imaging evaluation was&#xD;
             performed to ensure that the tumor was completely removed (clear margin);&#xD;
&#xD;
          5. Must have at least 1 resectable lesion (diameter ≥2 cm);&#xD;
&#xD;
          6. ECOG score &lt;2;&#xD;
&#xD;
          7. Child-Pugh score ≤7;&#xD;
&#xD;
          8. Hematology and organ function indicators should be met simultaneously: (1) White blood&#xD;
             cell count ≥3.0E+9/ L, neutrophil count ≥1.5E+9/ L, platelet countPlatelet count&#xD;
             ≥8.0E10/ L, hemoglobin ≥80g/L (2) Liver function: aspartate aminotransferase (AST)≤5&#xD;
             times normal value, alanine aminotransferase (ALT)≤5 times normal value, bilirubin ≤5&#xD;
             times normal value, serum albumin ≥28 g/L; (3) Renal function: creatinine (Cr)≤1.5&#xD;
             times normal limit, creatinine clearance ≥50 mL/min;&#xD;
&#xD;
          9. An estimated life expectancy of ≥3 months;&#xD;
&#xD;
         10. Participation in this clinical study voluntary, can cooperate with researchers to&#xD;
             carry out research, and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary hepatocellular carcinoma (HCC) has recurred in the past, or has other types of&#xD;
             liver cancer at the same time (such as intrahepatic cholangiocarcinoma, mixed type of&#xD;
             liver cancer);&#xD;
&#xD;
          2. Have a history of high fever or severe infection within 2 weeks prior to pretreatment,&#xD;
             or are expected to undergo systemic anti-infective therapy or systemic steroid therapy&#xD;
             during this trial;&#xD;
&#xD;
          3. Hepatic encephalopathy occurred within 2 weeks before pretreatment;&#xD;
&#xD;
          4. Previous or screening with autoimmune liver disease;&#xD;
&#xD;
          5. Screening with moderate or higher peritoneal effusion;&#xD;
&#xD;
          6. Clear neurological/psychiatric symptoms are known to be associated with brain&#xD;
             metastases and/or assessed by MMSE;&#xD;
&#xD;
          7. Anti-tumor therapy such as chemotherapeutic drugs, targeted drugs, radio frequency&#xD;
             ablation or minimally invasive intervention was received within 4 weeks before&#xD;
             pretreatment;&#xD;
&#xD;
          8. Have received or are expected to participate in this study within 4 weeks before&#xD;
             pretreatment to receive TIL required focus radiotherapy, or tumor evaluation focus&#xD;
             (target focus or non-target focus) radiotherapy, or radical radiotherapy;&#xD;
&#xD;
          9. Any toxic response resulting from previous anti-tumor treatment prior to pretreatment&#xD;
             did not return to grade 1 or below (CTCAE5.0 version);&#xD;
&#xD;
         10. Previous history of organ / stem cell transplantation or expected to be involved in&#xD;
             this trial for organ / stem cell transplantation;&#xD;
&#xD;
         11. Left ventricular ejection fraction (LVEF)&lt;45% or New York Heart Association (NYHA)≥&#xD;
             grade 2;&#xD;
&#xD;
         12. Known or private HIV infection or syphilis infection;&#xD;
&#xD;
         13. The previous 3 years other system primary malignant tumor history (except skin basal&#xD;
             cell carcinoma or cervical carcinoma in situ);&#xD;
&#xD;
         14. A known allergy to two or more non-homogeneous foods/drugs, or a known history of&#xD;
             allergies to pre-treated drugs, including cyclophosphamide, fludarbin, interleukin;&#xD;
&#xD;
         15. Pregnant, lactating women or within one year of having a family plan;&#xD;
&#xD;
         16. Participated in other clinical trials within 3 months prior to screening;&#xD;
&#xD;
         17. Other circumstances that the researchers considered inappropriate to participate in&#xD;
             the experiment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TIL; HCC; clinical research</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

